HighVista Strategies’s Ultragenyx Pharmaceutical RARE Stock Holding History

HighVista Strategies’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,328	Closed	-$483K	–	171
2025 Q1	$483K	Buy	+13,328	New	+$554K	0.19%	128
2023 Q4	–	Sell	-14,591	Closed	-$520K	–	142
2023 Q3	$520K	Buy	14,591 +7,265	+99%	+$288K	0.24%	104
2023 Q2	$338K	Buy	+7,326	New	+$340K	0.15%	131

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

HighVista Strategies's RARE Position: Q2 2025 in Review

HighVista Strategies sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 13,328 shares — an estimated $483K sold.

HighVista Strategies first reported a position in RARE in Q2 2023 and held it in 3 quarters. The position peaked at $520K in Q3 2023. 309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

HighVista Strategies reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
HighVista Strategies sold 13,328 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $483K.
HighVista Strategies first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and held it in 3 quarters.
HighVista Strategies's Ultragenyx Pharmaceutical position peaked at $520K in Q3 2023.
309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on HighVista Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.